secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001437749-24-011948
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Pharmaceuticals to restate 2022 and 2023 financials; R&D expenses understated by ~$3.9M
--------------------------------------------------------------------------------

- Audit Committee concluded prior financials for FY2022, Q3 2022, and all quarterly periods in FY2023 should no longer be relied upon due to errors in clinical trial expense accruals.
- FY2022 R&D expenses understated by approximately $3.9 million; net loss understated by same amount.
- Material weaknesses identified in internal controls over financial reporting related to clinical trial expense accruals and insufficient resources.
- Company expects to file restated financials in comprehensive 2023 10-K within 12b-25 extension period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924011948/0001437749-24-011948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924011948/rvph20240411_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-011948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer